209 related articles for article (PubMed ID: 33370388)
1. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.
Gonçalves D; Rignol G; Dellugat P; Hartmann G; Sarrazy Garcia S; Stavenhagen J; Santarelli L; Gouze E; Czech C
PLoS One; 2020; 15(12):e0244368. PubMed ID: 33370388
[TBL] [Abstract][Full Text] [Related]
2. Juvenile toxicity study of PF-07256472/recifercept, a recombinant human soluble fibroblast growth factor receptor 3, in 2-3-month-old cynomolgus monkeys.
Campion SN; Bowman CJ; Fuchs A; Karanian D; Rana P; Cappon GD
Birth Defects Res; 2023 Feb; 115(3):348-356. PubMed ID: 36367445
[TBL] [Abstract][Full Text] [Related]
3. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
Garcia S; Dirat B; Tognacci T; Rochet N; Mouska X; Bonnafous S; Patouraux S; Tran A; Gual P; Le Marchand-Brustel Y; Gennero I; Gouze E
Sci Transl Med; 2013 Sep; 5(203):203ra124. PubMed ID: 24048522
[TBL] [Abstract][Full Text] [Related]
4. HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
Ota S; Zhou ZQ; Romero MP; Yang G; Hurlin PJ
Hum Mol Genet; 2016 Oct; 25(19):4227-4243. PubMed ID: 27506979
[TBL] [Abstract][Full Text] [Related]
5. FGFR3 targeting strategies for achondroplasia.
Laederich MB; Horton WA
Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
[TBL] [Abstract][Full Text] [Related]
6. Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.
Martin L; Kaci N; Estibals V; Goudin N; Garfa-Traore M; Benoist-Lasselin C; Dambroise E; Legeai-Mallet L
Hum Mol Genet; 2018 Jan; 27(1):1-13. PubMed ID: 29040558
[TBL] [Abstract][Full Text] [Related]
7. PTH has the potential to rescue disturbed bone growth in achondroplasia.
Ueda K; Yamanaka Y; Harada D; Yamagami E; Tanaka H; Seino Y
Bone; 2007 Jul; 41(1):13-8. PubMed ID: 17466614
[TBL] [Abstract][Full Text] [Related]
8. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
Xie Y; Su N; Jin M; Qi H; Yang J; Li C; Du X; Luo F; Chen B; Shen Y; Huang H; Xian CJ; Deng C; Chen L
Hum Mol Genet; 2012 Sep; 21(18):3941-55. PubMed ID: 22634226
[TBL] [Abstract][Full Text] [Related]
9. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
Matsushita M; Hasegawa S; Kitoh H; Mori K; Ohkawara B; Yasoda A; Masuda A; Ishiguro N; Ohno K
Endocrinology; 2015 Feb; 156(2):548-54. PubMed ID: 25456072
[TBL] [Abstract][Full Text] [Related]
10. An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice.
Kimura T; Bosakova M; Nonaka Y; Hruba E; Yasuda K; Futakawa S; Kubota T; Fafilek B; Gregor T; Abraham SP; Gomolkova R; Belaskova S; Pesl M; Csukasi F; Duran I; Fujiwara M; Kavkova M; Zikmund T; Kaiser J; Buchtova M; Krakow D; Nakamura Y; Ozono K; Krejci P
Sci Transl Med; 2021 May; 13(592):. PubMed ID: 33952673
[TBL] [Abstract][Full Text] [Related]
11. Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia.
Saint-Laurent C; Garcia S; Sarrazy V; Dumas K; Authier F; Sore S; Tran A; Gual P; Gennero I; Salles JP; Gouze E
PLoS One; 2018; 13(4):e0195876. PubMed ID: 29652901
[TBL] [Abstract][Full Text] [Related]
12. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
Matsushita T; Wilcox WR; Chan YY; Kawanami A; Bükülmez H; Balmes G; Krejci P; Mekikian PB; Otani K; Yamaura I; Warman ML; Givol D; Murakami S
Hum Mol Genet; 2009 Jan; 18(2):227-40. PubMed ID: 18923003
[TBL] [Abstract][Full Text] [Related]
13. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
[TBL] [Abstract][Full Text] [Related]
14. [Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].
Tanaka H
Clin Calcium; 2010 Oct; 20(10):1490-6. PubMed ID: 20890030
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.
Komla-Ebri D; Dambroise E; Kramer I; Benoist-Lasselin C; Kaci N; Le Gall C; Martin L; Busca P; Barbault F; Graus-Porta D; Munnich A; Kneissel M; Di Rocco F; Biosse-Duplan M; Legeai-Mallet L
J Clin Invest; 2016 May; 126(5):1871-84. PubMed ID: 27064282
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Imaging of the Skull Base Synchondroses Demonstrate Prevention of a Premature Ossification After Recifercept Treatment in Mouse Model of Achondroplasia.
Rignol G; Garcia S; Authier F; Smith K; Tosello L; Marsault R; Dellugat P; Goncalves D; Brouillard M; Stavenhagen J; Santarelli L; Czech C; Gouze E
JBMR Plus; 2022 Feb; 6(2):e10568. PubMed ID: 35229060
[TBL] [Abstract][Full Text] [Related]
17. FGFR3 induces degradation of BMP type I receptor to regulate skeletal development.
Qi H; Jin M; Duan Y; Du X; Zhang Y; Ren F; Wang Y; Tian Q; Wang X; Wang Q; Zhu Y; Xie Y; Liu C; Cao X; Mishina Y; Chen D; Deng CX; Chang Z; Chen L
Biochim Biophys Acta; 2014 Jul; 1843(7):1237-47. PubMed ID: 24657641
[TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
Murakami S; Balmes G; McKinney S; Zhang Z; Givol D; de Crombrugghe B
Genes Dev; 2004 Feb; 18(3):290-305. PubMed ID: 14871928
[TBL] [Abstract][Full Text] [Related]
19. Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia.
Matsushita M; Esaki R; Mishima K; Ishiguro N; Ohno K; Kitoh H
Sci Rep; 2017 Aug; 7(1):7371. PubMed ID: 28785080
[TBL] [Abstract][Full Text] [Related]
20. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
